16:12 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis C virus (HCV) In vitro , cell culture, rat and dog studies identified a CYPA inhibitor that could help treat HCV. Chemical synthesis of analogs of the natural product sanglifehrin A and in...
20:15 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

NeuroVive reports preclinical data for cyclophilin D inhibitor program

NeuroVive Pharmaceutical AB (SSE:NVP; OTCQX:NVEPF) reported preclinical data showing that a cyclophilin D (CYPD) inhibitor from its NVP025 program led to a greater survival rate in a mouse model of lethal mitochondrial myopathy compared with...
21:12 , Jan 5, 2018 |  BC Week In Review  |  Company News

Allergan cutting jobs ahead of Restasis competition

Allergan plc (NYSE:AGN) announced details Thursday of a plan to reduce costs as it braces for potential generic competition to its blockbuster dry eye drug Restasis cyclosporine this year. The company will cut over 1,000...
23:00 , Jan 4, 2018 |  BC Extra  |  Company News

Allergan cutting jobs ahead of Restasis competition

Allergan plc (NYSE:AGN) announced details Thursday of a plan to reduce costs as it braces for potential generic competition to its blockbuster dry eye drug Restasis cyclosporine this year. The company will cut over 1,000...
01:38 , Jan 3, 2018 |  BC Extra  |  Company News

Allergan among companies unveiling price hikes

Allergan plc (NYSE:AGN) raised the price of 18 drugs by 9.5%, just under the company's pledge to limit yearly price increases to single digits, according to a Jefferies report. Allergan spokesperson Mark Marmur told BioCentury...
00:42 , Aug 12, 2017 |  BioCentury  |  Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...
17:57 , Feb 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Patient sample, rat and mouse studies suggest inhibiting CYPA could help treat ALS. Levels of CYPA were higher in CSF from sporadic ALS patients, a mouse model of familial ALS...
22:35 , Dec 1, 2016 |  BC Innovations  |  Product R&D

De-stressing about NASH

With a new use for an old compound, NeuroVive Pharmaceutical AB is positioning its cyclophilin inhibitor as a first-in-class treatment for NASH, adding the liver disease to the company’s repertoire of non-traditional mitochondrial disorders. The...
21:05 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis C virus (HCV); HIV/AIDS; coronavirus; viral infection Cell culture and in vitro studies identified phenylpyrrolidine-based inhibitors of CYPA , CYPB and CYPD that could help treat HCV, HIV/AIDS, coronavirus and other viral infections....
07:00 , Oct 31, 2016 |  BC Week In Review  |  Company News

NeuroVive, Arbutus Biopharma deal

NeuroVive and Arbutus terminated a 2014 deal that granted OnCore Biopharma Inc. exclusive, worldwide rights to NVP018 to treat HBV infection. OnCore merged with Tekmira Pharmaceuticals Corp. in 2015 to form Arbutus. NeuroVive regained all...